1.
Clin. transl. oncol. (Print)
; 9(9): 563-570, sept. 2007.
Artigo
em Inglês
| IBECS
| ID: ibc-123357
RESUMO
A summary of the current status of the application of peptidomimetics in cancer therapeutics as an alternative to peptide drugs is provided. Only compounds that are used in therapy or at least under clinical trials are discussed, using inhibitors of farnesyltransferase, proteasome and matrix metalloproteinases as examples (AU)